<DOC>
	<DOC>NCT00486291</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of VI-0521 compared to placebo in the glycemic management of obese diabetic adults.</brief_summary>
	<brief_title>Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Informed consent Type 2 Diabetes BMI 2742 Specified diet/exercise and/or diabetes medications BP &gt; 150/95 Stroke/MI/unstable cardiovascular disease within 6 months Clinically significant renal, hepatic, or psychiatric disease Unstable thyroid disease or replacement therapy Nephrolithiasis Obesity of known genetic or endocrine origin Participation in a formal weight loss program or lifestyle intervention History of glaucoma Pregnancy or breastfeeding Alcohol abuse Eating disorder Excluded medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Diabetes, Obese diabetics</keyword>
</DOC>